Haemonetics Corporation HAE

Full chart Compare
Set alert

Price alert · HAE

All alert types
123.18 USD -4.24 (-3.33%)

Nov 5, 2026, 2:36 PM EST

121.22 Day range 132.00
51.00 52-week range 132.00
YTD
+53.69%
1 year
+142.86%
Market cap
5.62B
Revenue (ttm)
1.35B
Profit margin
7.12%
EPS (ttm)
2.07
Shares out
45.50M
P/E ratio
59.63
Forward P/E
22.06
YTD return
+53.69%
1-year return
+142.86%
Volume
601.51K
Avg volume
710.36K
Open
126.06
Previous close
127.42
Day's range
121.22 – 132.00
52-week range
51.00 – 132.00
Beta
0.59
Analysts
Buy
Price target
124.50 (+1.1%)
Earnings date
Nov 5, 2026

2Y +47.62 (+63.51%)

5075100125Nov 24Jan 25Mar 25May 25Jul 25Sep 25Nov 25Jan 26Mar 26May 26Jul 26Sep 26122.60

Key statistics

Enterprise value
6.42B
PEG ratio
1.91
Price / sales
4.29
Price / book
6.92
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
5.60%
Free cash flow
312.84M
Total cash
224.52M
Total debt
1.17B
Return on equity
11.20%
Short % of float
8.82%
50-day average
110.44
200-day average
79.11

Financials — quick view

All financials
HAE Revenue — quarterly 339.38M
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
HAE Net income — quarterly 33.01M
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
HAE EPS — quarterly 0.73
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026

Earnings

HAE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 27, 20261.29———
Aug 6, 2026Jun 27, 20261.081.14+0.06+5.56%
May 7, 2026Mar 28, 20261.281.29+0.01+0.78%
Feb 5, 2026Dec 27, 20251.271.31+0.04+3.15%
Nov 6, 2025Sep 27, 20251.121.27+0.15+13.39%
Aug 7, 2025Jun 28, 20251.011.10+0.09+8.91%

Upgrades / downgrades

HAE analyst upgrades and downgrades
DateFirmActionFromTo
Oct 9, 2026Barrington ResearchmainOutperformOutperform
Oct 9, 2026MizuhomainOutperformOutperform
Oct 8, 2026BTIGmainBuyBuy
Sep 17, 2026CitigroupupNeutralBuy
Sep 3, 2026Raymond JamesmainOutperformOutperform
Aug 21, 2026BairdmainOutperformOutperform

About Haemonetics Corporation

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on HAE — it syncs with the Stock Master app.

Insider holders

HAE insider holders
InsiderRelationLatest transactionDateShares held
ABERNATHY ROBERT EDirectorStock Award(Grant)Jul 23, 202627,519
BASIL MICHELLE LGeneral CounselStock Award(Grant)May 14, 202668,829
DARECCA JAMESChief Financial OfficerStock Award(Grant)May 14, 202654,444
DOCKENDORFF CHARLES JDirectorStock Award(Grant)Jul 23, 202525,041
GALVIN ROYOfficerStock Award(Grant)May 14, 202639,882
KROLL MARK WDirectorStock Award(Grant)Jul 23, 202627,295

Institution ownership

HAE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.99%5,909,258752.96MJun 29, 2026
Neuberger Berman Group, LLC9.19%4,179,443532.54MJun 29, 2026
Vanguard Portfolio Management LLC5.60%2,546,394324.46MJun 29, 2026
AQR Capital Management, LLC4.98%2,266,489288.80MJun 29, 2026
Vanguard Capital Management LLC4.53%2,059,578262.43MJun 29, 2026
Ariel Investments, LLC4.53%2,060,966262.61MJun 29, 2026

Fund ownership

HAE fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,621,301206.59MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%1,441,654183.70MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.62%1,194,166152.16MSep 29, 2026
NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund2.59%1,179,168150.25MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%1,041,356132.69MJun 29, 2026
Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com1.35%614,82478.34MJun 29, 2026